Global InformationBristol Myers Squibb information
 | |
 A Bristol Myers Squibb research and development facility in Lawrence, New Jersey (corporate headquarters since July 2023) | |
Trade name | Bristol Myers Squibb |
|---|---|
| Formerly | Bristol-Myers Company (1887–1989) |
| Company type | Public |
Traded as |
|
| Industry | Pharmaceuticals |
| Predecessors | Squibb Corporation (1858–1989) |
| Founded | 1887 |
| Founders |
|
| Headquarters |
|
Area served | Worldwide |
Key people |
|
| Revenue |  US$45.01 billion (2023) |
Operating income |  US$8.44 billion (2023) |
Net income | US$8.04 billion (2023) |
| Total assets | US$95.16 billion (2023) |
| Total equity | US$29.43 billion (2023) |
Number of employees | 34,100 (2023) |
| Website | bms |
| Footnotes / references [1] | |
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey,[2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.[1]
Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
BMS's primary research and development (R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad; Bangalore India[3] and Wirral, United Kingdom.[4][5] BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).[6]
- ^ a b "Bristol Myers Squibb 2023 Annual Report (Form 10-K)". SEC.gov. U.S. Securities and Exchange Commission. 13 February 2024.
- ^ Bristol-Myers Squibb Company (27 July 2023). "Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 (Form 8-K)". SEC.gov. U.S. Securities and Exchange Commission. Retrieved 2 August 2023.
- ^ "Bristol Myers Squibb to invest Rs 800 crore to set up facility in Hyderabad for drug development, IT". The Economic Times. 23 February 2023.
- ^ "Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park" (Press release). Archived from the original on 29 September 2012. Retrieved 16 May 2012.
- ^ "Worldwide Research and Development Facilities – Bristol Myers Squibb". www.bms.com. Archived from the original on 7 June 2020. Retrieved 7 June 2020.
- ^ "Bristol-Myers Squibb to lay off 149 as Wallingford, Connecticut, site nears closure". Fiercepharma.com. 17 July 2018. Archived from the original on 4 February 2019. Retrieved 3 February 2019.